Braveheart Bio Secures $185 Million Series A Financing to Advance Global Development of BHB-1893 for Hypertrophic Cardiomyopathy

On November 5, 2025, local time, a startup company focused on the treatment of hypertrophic cardiomyopathy (HCM)Braveheart Bio Announcement of Completion$185 million(RMB 1.3 billion+) Series A financing. This round was co-led by multiple top-tier life sciences investment firms, including Andreessen Horowitz, Forbion, OrbiMed, Enavate Sciences (a platform under Patient Square Capital), and Frazier Life Sciences.

Notably, this roster of investors boasts an all-star lineup, comprising established “old money” funds that specialize in industry leaders. Among them, Forbion is one of Europe’s most competitive and influential life sciences venture capital firms, having successfully facilitated the approval of multiple breakthrough therapies through its expertise in identifying, nurturing, and guiding life sciences companies. OrbiMed stands as one of the most influential and well-capitalized investment institutions in the global healthcare sector, leveraging its robust global resources to build world-class healthcare companies.

Behind the willingness of a roster of high-profile investors to foot the bill is Braveheart Bio’s sole pipeline asset—the cardiac myosin inhibitor HRS-1893, now renamed BHB-1893.

Less than two months ago, on September 5, Hengrui Medicine announced that it had entered into an exclusive licensing agreement with Braveheart Bio for BHB-1893, a small-molecule cardiac myosin inhibitor independently developed by Hengrui.

Under the terms of the agreement, Hengrui Medicine has licensed to Braveheart Bio the exclusive rights to develop, manufacture, and commercialize BHB-1893 globally outside of China for consideration. Braveheart Bio will pay Hengrui Medicine an upfront payment of $65 million (comprising $32.5 million in cash and $32.5 million worth of equity in Braveheart Bio) and a near-term milestone payment of $10 million upon completion of technology transfer, totaling $75 million. In addition, Hengrui Medicine will be eligible to receive up to $1.013 billion in clinical development and sales-related milestone payments, as well as corresponding sales royalties.

According to incomplete statistics from VBInsight, this $185 million deal ranks among the top 10 global healthcare Series A financing rounds of 2025, a standout achievement in a year marked by continued caution in the primary market. Therefore, to understand this financing round, one must first grasp the value of the company’s core asset, BHB-1893. It is not merely an ordinary investigational molecule, but a game-changer for hypertrophic cardiomyopathy (HCM), a disease area that has long lacked effective therapeutic options.

Hypertrophic cardiomyopathy (HCM) is a primary cardiomyopathy characterized prominently by left ventricular hypertrophy. It is the most common hereditary heart disease and the leading cause of sudden cardiac death in adolescents and athletes. Based on whether the peak pressure gradient across the left ventricular outflow tract at rest or after provocation is <30 mmHg, HCM is classified into obstructive and non-obstructive types. Compared with patients with non-obstructive HCM, those with obstructive HCM have lower survival rates, and alleviation of obstruction helps reduce the risk of mortality. Currently, for the treatment of obstructive HCM, cardiac myosin inhibitors have received a Class IB recommendation in the "2025 Chinese Guidelines for the Comprehensive Management of Cardiomyopathies."

Traditional management of hypertrophic cardiomyopathy (HCM) has largely focused on symptomatic relief, such as using beta-blockers to alleviate symptoms or performing invasive septal myectomy. In contrast, cardiac myosin inhibitors work by reducing excessive myocardial contractility at its source. By directly targeting the molecular motor of myocardial contraction—akin to installing an intelligent governor in an overactive engine—they effectively mitigate left ventricular outflow tract obstruction and improve patients’ cardiac function and quality of life. This mechanism represents an advance over traditional symptomatic therapies, embodyingHCMA Paradigm Shift in Treatment.

BHB-1893 can specifically inhibit the activity of cardiac myosin ATPase, normalize myocardial contractile performance, reduce left ventricular hypertrophy, and improve diastolic compliance.

The global prevalence of hypertrophic cardiomyopathy (HCM) is estimated to exceed 2 million patients. Previously, the market value remained underexploited due to a scarcity of effective therapies. With advancements in diagnostic technologies and heightened awareness of treatment, the HCM pharmaceutical market is now regarded as the next billion-dollar “gold mine” in the cardiovascular field. The therapeutic area in which BHB-1893 competes represents precisely such a blue-ocean market with substantial growth potential and urgent unmet needs.

According to Hengrui Medicine, BHB-1893 has undergone multiple clinical trials, with its Phase I clinical trial data presented at the 2025 European Society of Cardiology (ESC) Congress; furthermore, the Phase II clinical study has met its predefined endpoints. In addition, the Phase III clinical trial of this product for the treatment of obstructive hypertrophic cardiomyopathy was initiated in June 2025.

In other words, the druggability of BHB-1893 has been preliminarily validated. For international capital, in-licensing a late preclinical or early clinical asset from a company with an international reputation like Hengrui carries far lower risk than investing in a completely unproven new platform. The financing deal itself serves as an “implicit endorsement” by Hengrui Medicine of its R&D capabilities.

Braveheart Bio has obtained the exclusive global rights to BHB-1893 outside of China from Hengrui Medicine. This means that Braveheart Bio must bear the substantial costs of conducting large-scale, multicenter clinical trials in major markets such as Europe and the United States. International clinical development is costly, particularly in the cardiovascular field, where large patient populations and long-term follow-up are required to verify efficacy and safety. The funds from this financing round serve as an “ammunition depot” for BHB-1893’s push into the global market, ensuring that its clinical development can advance rapidly in accordance with international standards.

Furthermore, as previously mentioned, lead investors such as OrbiMed and Forbion are not ordinary financial investors. They are typical “value-added” capital firms with extensive global healthcare resource networks. This prestigious lineup undoubtedly reduces the operational risks for Braveheart Bio as a startup and enhances the probability of successfully launching its products in the global market. This further demonstrates that the value of Chinese innovative drugs is no longer confined to the domestic market; their innovation quality is fully capable of attracting top-tier international capital and being developed according to the highest global standards.

Of course, risks are not absent. Braveheart Bio currently has only a single pipeline, and any safety misstep during subsequent clinical development and regulatory approval could halve its valuation. Moreover, Braveheart Bio’s decision to directly initiate global multicenter pivotal clinical trials in 2026 indicates that the company will skip Phase IIb, trading capital for time.

Against the backdrop of a challenging primary market financing environment, Braveheart Bio’s fundraising success serves as a much-needed boost, demonstrating to all Chinese biotech companies that possessing hard-core assets with genuine global innovativeness and substantial market potential can not only generate upfront revenue through license-out deals but also serve as a cornerstone for attracting international capital to establish new entities, thereby enabling deep participation in and sharing of the dividends from the global market.

Meanwhile, this financing round powerfully demonstrates that the so-called “capital winter” is, in essence, a “winter for mediocre assets.” Capital always maintains its highest enthusiasm and strongest liquidity for innovations with truly disruptive potential that can address significant unmet clinical needs. The market is becoming more rational, with funds flowing toward the most valuable innovation highlands with unprecedented precision.